Eli Lilly’s Cyramza has a new string to its bow after the FDA approved it as a second-line treatment for certain liver cancer patients, and received a further boost as the FDA removed a boxed warning from its label. The US regulator first approved...
Original Article: Lilly gets fifth use for Cyramza with FDA liver cancer nod